Feb 19, 2020   SOURCE: PR NewsWire

Global Optic Nerve Diseases Pipeline Study, 2020: Treatment, Products, Drugs, Key Players

DUBLIN, Feb. 19, 2020 /PRNewswire/ -- The "Optic Nerve Diseases - Pipeline Insights, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Optic Nerve Diseases Pipeline Insights, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Optic Nerve Diseases market.

A detailed picture of the Optic Nerve Diseases pipeline landscape is provided, which includes the disease overview and Optic Nerve Diseases treatment guidelines. The assessment part of the report embraces in-depth Optic Nerve Diseases commercial assessment and clinical assessment of the Optic Nerve Diseases pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Optic Nerve Diseases collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The report provides insights into:

    --  All of the companies that are developing therapies for the treatment of
        Optic Nerve Diseases with aggregate therapies developed by each company
        for the same.
    --  Different therapeutic candidates segmented into early-stage, mid-stage
        and late stage of development for the Optic Nerve Diseases treatment.
    --  Optic Nerve Diseases key players involved in targeted therapeutics
        development with respective active and inactive (dormant or
        discontinued) projects.
    --  Drugs under development based on the stage of development, route of
        administration, target receptor, monotherapy or combination therapy, a
        different mechanism of action, and molecular type.
    --  Detailed analysis of collaborations (company-company collaborations and
        company-academia collaborations), licensing agreement and financing
        details for future advancement of Optic Nerve Diseases market.

Scope of the Report

    --  The Optic Nerve Diseases report provides an overview of therapeutic
        pipeline activity and therapeutic assessment of the products by
        development stage, product type, route of administration, molecule type,
        and MOA type for Optic Nerve Diseases across the complete product
        development cycle, including all clinical and nonclinical stages.
    --  It comprises of detailed profiles of Optic Nerve Diseases therapeutic
        products with key coverage of developmental activities, including
        technology, collaborations, licensing, mergers and acquisition, funding,
        designations and other product-related details.
    --  Detailed Optic Nerve Diseases research and development progress and
        trial details, results wherever available, are also included in the
        pipeline study.
    --  Coverage of dormant and discontinued pipeline projects along with the
        reasons if available across Optic Nerve Diseases.

Key Topics Covered

1. Report Introduction

2. Optic Nerve Diseases
2.1. Overview
2.2. History
2.3. Optic Nerve Diseases Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Optic Nerve Diseases Diagnosis
2.6.1. Diagnostic Guidelines

3. Optic Nerve Diseases Current Treatment Patterns
3.1. Optic Nerve Diseases Treatment Guidelines

4. Optic Nerve Diseases - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Optic Nerve Diseases companies collaborations, Licensing, Acquisition - Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Optic Nerve Diseases Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Optic Nerve Diseases Acquisition Analysis

5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target

6. Optic Nerve Diseases Late Stage Products (Phase-III)

7. Optic Nerve Diseases Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Optic Nerve Diseases Discontinued Products

13. Optic Nerve Diseases Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table

14. Optic Nerve Diseases Key Companies

15. Optic Nerve Diseases Key Products

16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being Dormant
16.2. Discontinued Products
16.2.1. Reasons for the Discontinuation

17. Optic Nerve Diseases Unmet Needs

18. Optic Nerve Diseases Future Perspectives

19. Optic Nerve Diseases Analyst Review

Companies Mentioned 

    --  GenSight Biologics
    --  Stealth BioTherapeutics Inc.
    --  Regenera Pharma Ltd.
    --  GenSight Biologics
    --  Clene Nanomedicine
    --  Clene Australia Pty. Ltd.
    --  Hoffmann-La Roche
    --  Chugai Pharmaceutical
    --  MedImmune LLC
    --  Bio-Thera Solutions
    --  RemeGen

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/fmsivt

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-optic-nerve-diseases-pipeline-study-2020-treatment-products-drugs-key-players-301007379.html

SOURCE Research and Markets